Bromocriptine Administration Reduces Hyperphagia and Adiposity and Differentially Affects Dopamine D2 Receptor and Transporter Binding in Leptin-Receptor-Deficient Zucker Rats and Rats with Diet-Induced Obesity

Lisa M. Davis,Michael Michaelides,Lawrence J. Cheskin,Timothy H. Moran,Susan Aja,Paul A. Watkins,Zhengtong Pei,Carlo Contoreggi,Karen McCullough,Bruce T. Hope,Gene Jack Wang,Nora D. Volkow,Panayotis K. Thanos

Bromocriptine Administration Reduces Hyperphagia and Adiposity and Differentially Affects Dopamine D2 Receptor and Transporter Binding in Leptin-Receptor-Deficient Zucker Rats and Rats with Diet-Induced Obesity

2009

Lisa M. Davis
Michael Michaelides
Lawrence J. Cheskin
Timothy H. Moran
Susan Aja
Paul A. Watkins
Zhengtong Pei
Carlo Contoreggi
Karen McCullough
Bruce T. Hope
Gene Jack Wang
Nora D. Volkow
Panayotis K. Thanos

Background: The dopamine (DA) D2 receptor (D2R) agonist bromocriptine (BC) decreases body fat in animal and human models and increases lean muscle mass, improves glucose

Keywords:

Dopamine transporter
Dopamine
Agonist
Dopamine agonist
Bromocriptine
Internal medicine
Endocrinology
Dopamine receptor D2
Diet-induced obese
Biology
Leptin receptor
Leptin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations